[Invasive disseminated aspergillosis in combined immunosuppressive therapy in systemic lupus erythematosus].
Teuber
G
G
Schwarting
A
A
Mildenberger
P
P
Schmidt-Brücken
G
G
Moll
R
R
Bornemann
A
A
Wandel
E
E
Wanitschke
R
R
Meyer zum Büschenfelde
K H
KH
D000368:Aged; D001228:Aspergillosis / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D005260:Female; D016469:Fungemia / Q000139:chemically induced / Q000276:immunology / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D009894:Opportunistic Infections / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D011239:Prednisolone / Q000009:adverse effects* / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011239:Prednisolone
Invasive disseminierte Aspergillose unter kombinierter immunsuppressiver Therapie bei systemischem Lupus erythematodes.